Why Hepatitis C Screening Went From a Birth Cohort to Nearly Every Adult

Why hepatitis C screening became a one-time test for nearly every adult

In 2020 the U.S. Preventive Services Task Force stopped asking what year you were born and began recommending a one-time hepatitis C test for essentially every adult aged 18 to 79, a Grade B recommendation published in JAMA. That replaced the 2013 policy, which screened only adults born between 1945 and 1965 plus people who carried specific risk factors. Two forces drove the change: the infection moved into younger adults faster than a birth-year filter could follow, and direct-acting antiviral drugs turned a stubborn chronic disease into one cured in more than 95 percent of treated patients. When both the number of missed infections and the value of catching them rise at once, the case for broad screening rises with them.

How a screening recommendation is actually built

The Task Force does not ask whether a test exists or works in a laboratory. It asks a narrower question: does testing a defined group of people produce more benefit than harm, and how certain can the evidence make us? Benefits and harms are weighed together, then graded. A Grade B rating signals at least moderate certainty of a moderate net benefit, the threshold at which the Task Force recommends offering a service routinely. Nothing about the hepatitis C virus itself changed between 2013 and 2020. What changed were the two inputs that decide net benefit: who is getting infected, and what happens after a positive result.

Why birth-year targeting made sense in 2013

For years, chronic hepatitis C in the United States was concentrated in one generation. People born between 1945 and 1965 carried a disproportionate share of long-standing infections, many acquired decades earlier before the blood supply was screened and before the virus was even identified. Targeting that birth cohort was an efficient way to find the most cases with the fewest tests. It also fit the treatment reality of the time. Interferon-based regimens were long, poorly tolerated, and far from reliably curative, so the downstream reward for finding an infection was real but limited. A focused strategy matched a focused benefit.

What changed, part one: the epidemiology moved

By the late 2010s the map no longer matched the territory. The Task Force noted that cases of acute hepatitis C rose roughly 3.8-fold between 2010 and 2017, driven largely by injection drug use and, in part, by better surveillance. The steepest increases were in adults aged 20 to 39, a group a 1945-to-1965 filter cannot see. The Centers for Disease Control and Prevention, issuing parallel guidance in 2020, described the same pattern: the highest rates of new infection fell among people in their twenties and thirties, tracking closely with the rise in injection drug use. A birth-cohort strategy built around older Americans was, by design, blind to the fastest-growing segment of new infection.

What changed, part two: the treatment became curative

The second input shifted even more dramatically. Direct-acting antivirals, taken as pills over roughly 8 to 12 weeks, achieve sustained virologic response, the accepted marker of cure, in well over 95 percent of adults across viral genotypes, with far fewer harms than the interferon era imposed. That single fact reweights the entire calculation. When treatment is short, well tolerated, and highly effective, a positive screening result can lead to cure and to the prevention of cirrhosis, liver cancer, and onward transmission. The benefit side of the ledger grew, and it grew for a disease that is often silent for years before it damages the liver.

The arithmetic of screening a whole population

Broadening a test to a general population always carries a cost. In a lower-prevalence group, a larger share of initial positives are false alarms, which is why hepatitis C screening is a two-step process: an antibody test, and, if that is positive, a confirmatory test for viral RNA before anyone is called infected. The Task Force weighed those harms, including anxiety and follow-up testing, against the benefit of curing infections that would otherwise be found late or not at all, and judged the balance favorable across the 18-to-79 range. The recommendation is deliberately specific about frequency. Most adults need the test only once. People with continued exposure, such as ongoing injection drug use, warrant periodic retesting, because a single result cannot account for a future infection.

What the recommendation does and does not say

Precision matters here. One-time screening is not annual screening for everyone; the routine test is a single check for most adults, with repeat testing reserved for continued risk. Screening is also not diagnosis, since a positive antibody result is confirmed by an RNA test before treatment. And a recommendation to offer testing is not a mandate that any individual be tested. This article is educational and not medical advice; whether and when to test is a decision to make with a clinician who knows your history.

The larger lesson reaches beyond one virus. Screening policy is not fixed. It is a running calculation that updates when the disease or the treatment changes underneath it. Hepatitis C changed on both axes at once, and the recommendation followed the evidence from a birth year to nearly every adult.